- Information & Support
- Uveal Melanoma
Have you been diagnosed with uveal melanoma?
Melanoma Focus funded the development of Uveal Melanoma National Guidelines, which were developed by a panel of experts, made up of clinicians and patients.
“Uveal melanoma is now classified as a distinct disease entity (rather than a different form of cutaneous melanoma) and has been granted ‘orphan status’ which means that there are some incentives to encourage new medicines to be developed. It is an exciting time for uveal melanoma as there are new treatments in development which will hopefully be available outside of clinical trials soon.”
Dr Paul Nathan, Trustee (consultant medical oncologist, Mount Vernon Cancer Centre)
What is uveal melanoma?
Uveal melanoma is a cancer of the eye involving the iris, ciliary body or choroid (known as the uvea).
Tumours arise from the pigment cells in the eye called melanocytes. This is the same as melanoma skin cancer, but uveal melanoma is different and is treated differently.
Uveal melanoma is treated in three specialised centres in England: Liverpool, London and Sheffield. These are called “supra-regional” centres.
Uveal melanoma that has spread (called metastatic uveal melanoma) requires the input of many
different highly-specialised healthcare professionals. Patients are treated at centres with specialist
cancer and liver teams.
The prognosis for uveal melanoma that has spread is usually very poor. There is no
chemotherapy that has been found to be effective for metastatic uveal melanoma so patients have to rely on experimental treatments.
Ocular Pharmacology & Genetics Group (OPGG), based in the School of Biomolecular and Biomedical Science, Conway Institute, University College Dublin marked Melanoma Awareness Month 2021 with the release of this video: